127 related articles for article (PubMed ID: 21319052)
1. Usefulness of combined PET/CT for patient with epithelial ovarian cancer showing recurrence based on tumor marker CA125.
Muramatsu T; Yamashita E; Takahashi K; Sugiyama T; Tsukada H; Kondo A; Hirasawa T; Murakami M; Yasuda S; Mikami M
Tokai J Exp Clin Med; 2007 Mar; 32(1):23-7. PubMed ID: 21319052
[TBL] [Abstract][Full Text] [Related]
2. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
[TBL] [Abstract][Full Text] [Related]
3. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
Innao P; Pothisuwan M; Pengsa P
Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
[TBL] [Abstract][Full Text] [Related]
4. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
[TBL] [Abstract][Full Text] [Related]
5. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
6. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
Antunovic L; Cimitan M; Borsatti E; Baresic T; Sorio R; Giorda G; Steffan A; Balestreri L; Tatta R; Pepe G; Rubello D; Cecchin D; Canzonieri V
Clin Nucl Med; 2012 Aug; 37(8):e184-8. PubMed ID: 22785525
[TBL] [Abstract][Full Text] [Related]
7. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
Kim CK; Park BK; Choi JY; Kim BG; Han H
J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
[TBL] [Abstract][Full Text] [Related]
8. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
[TBL] [Abstract][Full Text] [Related]
9. Management of epithelial ovarian cancer from diagnosis to restaging: an overview of the role of imaging techniques with particular regard to the contribution of 18F-FDG PET/CT.
Musto A; Grassetto G; Marzola MC; Rampin L; Chondrogiannis S; Maffione AM; Colletti PM; Perkins AC; Fagioli G; Rubello D
Nucl Med Commun; 2014 Jun; 35(6):588-97. PubMed ID: 24535383
[TBL] [Abstract][Full Text] [Related]
10. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.
Murakami M; Miyamoto T; Iida T; Tsukada H; Watanabe M; Shida M; Maeda H; Nasu S; Yasuda S; Yasuda M; Ide M
Int J Gynecol Cancer; 2006; 16 Suppl 1():99-107. PubMed ID: 16515575
[TBL] [Abstract][Full Text] [Related]
11. A joint model based on longitudinal CA125 in ovarian cancer to predict recurrence.
Chang C; Chiang AJ; Chen WA; Chang HW; Chen J
Biomark Med; 2016; 10(1):53-61. PubMed ID: 26565119
[TBL] [Abstract][Full Text] [Related]
12. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
13. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer.
Nakamura K; Hongo A; Kodama J; Hiramatsu Y
Acta Med Okayama; 2012; 66(1):53-60. PubMed ID: 22358139
[TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread.
Hynninen J; Auranen A; Carpén O; Dean K; Seppänen M; Kemppainen J; Lavonius M; Lisinen I; Virtanen J; Grénman S
Gynecol Oncol; 2012 Jul; 126(1):64-8. PubMed ID: 22542580
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
[TBL] [Abstract][Full Text] [Related]
17. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
Bristow RE; Giuntoli RL; Pannu HK; Schulick RD; Fishman EK; Wahl RL
Gynecol Oncol; 2005 Nov; 99(2):294-300. PubMed ID: 16051330
[TBL] [Abstract][Full Text] [Related]
18. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
19. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study.
Signorelli M; Guerra L; Pirovano C; Crivellaro C; Fruscio R; Buda A; Cuzzucrea M; Elisei F; Ceppi L; Messa C
Gynecol Oncol; 2013 Nov; 131(2):395-9. PubMed ID: 23988414
[TBL] [Abstract][Full Text] [Related]
20. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
